Trial Profile
A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Filgrastim
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Allergy Therapeutics
- 14 Apr 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 09 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.